Figure 5.

COX2 expression in healthy control and baseline CRC patients (a), the change in COX2 expression after 3 and 6 months of FP therapy normalised to their baseline levels (b) and the COX2 expression in adenocarcinoma and mucinous tumours in baseline CRC patients (c).

Total RNA was extracted from the isolated lymphocytic cell pellets of healthy control and CRC patients at baseline and after 3 and 6 months of FP therapy. RNA was converted into cDNA, and then RT-PCR amplification was conducted with the designed COX2 gene sequence.